Annual Report of the Company for the Financial Year 2024-25 along with Notice of the Fourteenth Annual General Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fabino Enterprises Ltd (formerly Fabino Life Sciences Ltd) submitted its 14th Annual Report for FY 2024-25 to BSE, along with the AGM notice. The 14th AGM is scheduled for Monday, September 22, 2025 at 11:00 AM at the registered office in Sonipat, Haryana. On a standalone basis, total income jumped sharply to Rs. 1,832.46 lakhs from Rs. 608.41 lakhs, while profit after tax rose to Rs. 13.19 lakhs (from Rs. 4.76 lakhs), with EPS of Rs. 0.63. On a consolidated basis, revenue fell to Rs. 1,832.63 lakhs from Rs. 2,109.33 lakhs, though PAT improved to Rs. 6.11 lakhs from Rs. 3.58 lakhs. The Board has not recommended any dividend for the year. Key items include approval of financial statements, re-appointment of Mr. Arihant Jain (rotational), and regularization of Mrs. Vandana Jain (mother of MD Aditya Jain) as Executive Director. Several board and KMP changes took place during FY 2024-25, including a change in Company Secretary.
Routine annual filing, but standalone results show a strong revenue and profit rebound, while consolidated revenue declined—suggesting weakness in the subsidiary (Upender Metaplast Pvt Ltd). No dividend and the appointment of the MD's mother as Executive Director are minor governance points for shareholders to watch.